Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, with its lead asset Attruby (acoramidis) approved in January 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare cardiac disease affecting approximately 300,000-500,000 patients globally. The company operates a portfolio model with 15+ programs across multiple subsidiaries targeting genetically defined patient populations, competing against Pfizer's Vyndaqel franchise in ATTR-CM while developing earlier-stage assets in achondroplasia, limb-girdle muscular dystrophy, and oncology. Stock performance is driven by Attruby commercial uptake trajectory, pipeline clinical readouts, and the company's ability to achieve cash flow breakeven through rare disease commercialization.
BridgeBio generates revenue through direct commercialization of Attruby in the US rare disease market, targeting cardiologists and ATTR-CM specialists with a focused 150-200 person sales force. The company leverages genetic testing and biomarker identification to find undiagnosed patients, competing on clinical differentiation (all-cause mortality reduction vs. Pfizer's Vyndaqel) and potentially favorable dosing (once-daily oral). Pricing power is substantial in rare disease (~$200,000+ annual wholesale acquisition cost), with gross margins exceeding 95% due to low manufacturing costs for small molecule drugs. The portfolio model allows capital allocation across multiple shots-on-goal while maintaining optionality to spin out or partner programs, though current focus is singular: achieving Attruby commercial success to fund operations.
Attruby quarterly prescription data and revenue trajectory - market expects 15,000-20,000 patients on therapy at steady state vs. current early launch phase
Clinical trial readouts from pipeline programs, particularly infigratinib Phase 3 data in achondroplasia (pediatric growth disorder) and BBP-418 data in muscular dystrophy
Competitive dynamics with Pfizer's Vyndaqel/Vyndamax franchise - market share capture, head-to-head trial results, and physician adoption patterns
Cash runway updates and path to profitability - company had $1.1B cash at recent reporting with $500M annual burn rate, implying 2+ years runway
FDA regulatory decisions on pipeline assets and potential label expansions for Attruby into earlier-stage ATTR-CM or polyneuropathy indications
Competitive obsolescence from next-generation ATTR therapies including gene silencing (Alnylam's patisiran/vutrisiran) and CRISPR-based gene editing approaches that could offer superior efficacy or convenience vs. stabilizer mechanism
Pricing pressure from Medicare drug price negotiation under Inflation Reduction Act - Attruby could face mandated discounts if selected for negotiation after 7-9 years on market, capping long-term revenue potential
Regulatory risk from FDA scrutiny on accelerated approval pathways and requirements for confirmatory trials - any safety signals or efficacy questions could trigger label restrictions
Pfizer's Vyndaqel franchise dominance with 7+ years head start, established relationships with 1,500+ cardiologists, and strong clinical data creates high switching costs - BridgeBio must prove differentiation to capture share
Pipeline program failures or delays could eliminate growth optionality beyond Attruby, leaving company as single-asset story vulnerable to competitive or regulatory setbacks
Larger pharmaceutical companies (Novartis, Roche, BMS) entering rare disease space through M&A or internal development, bringing superior commercial capabilities and capital resources
Equity dilution risk if Attruby launch underperforms and company requires additional capital raises before reaching cash flow breakeven - at $500M annual burn, potential 20-30% dilution if financing needed
Negative working capital dynamics during launch phase as company builds inventory and extends payment terms to specialty pharmacies while awaiting reimbursement
Contingent value rights (CVRs) or milestone payments to acquisition targets could create unexpected cash outflows if pipeline programs succeed, though this represents upside risk
low - Rare disease treatments are medically necessary, non-discretionary healthcare spending with minimal correlation to GDP growth. ATTR-CM is a progressive, fatal disease where patients and physicians prioritize efficacy over economic conditions. Insurance coverage (Medicare, commercial) insulates demand from consumer spending cycles. However, severe recessions could pressure hospital budgets and diagnostic testing rates, potentially slowing new patient identification.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress NPV of future cash flows for pre-profitable biotech, disproportionately impacting valuation multiples - BridgeBio trades at 40x P/S, making it sensitive to risk-free rate changes that affect growth stock valuations; (2) Increased financing costs if company needs to raise additional capital through convertible debt, though current $1.1B cash position provides near-term buffer. Conversely, falling rates would benefit valuation multiples and reduce cost of capital for future financings.
Minimal direct credit exposure as rare disease drugs are reimbursed primarily through Medicare Part D and commercial insurance with high coverage rates (>80% for ATTR-CM therapies). The company has negative net debt position with $1.1B+ cash and minimal borrowings. Credit market conditions matter indirectly for future financing access if cash burn continues, but strong balance sheet and commercial-stage asset reduce refinancing risk compared to clinical-stage peers.
growth - BridgeBio attracts growth-oriented biotech investors focused on commercial execution of newly launched rare disease therapies with multi-billion peak sales potential. The 110% one-year return and 40x P/S valuation reflect momentum-driven trading as Attruby launch progresses. Institutional healthcare specialists (Perceptive Advisors, RA Capital, Farallon) dominate ownership given clinical/commercial expertise required. Not suitable for value or income investors given negative earnings, no dividend, and high valuation multiples. Risk-tolerant growth investors accept binary clinical/commercial risk for asymmetric upside if Attruby captures significant ATTR-CM market share.
high - Biotech stocks exhibit elevated volatility with beta typically 1.3-1.8x market. BridgeBio's 52% six-month return demonstrates momentum sensitivity. Single-asset commercial risk creates event-driven volatility around quarterly earnings (prescription data), clinical readouts, and competitive developments. Options market implies 60-80% annualized volatility. Small-cap biotech positioning ($14B market cap) amplifies price swings on modest volume changes. Volatility should compress if Attruby achieves sustained commercial traction and company approaches profitability, but remains elevated vs. large-cap pharma until revenue diversification occurs.
